Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Factors affecting the choice between originators or biosimilars among participants who exclusively used one type. Among the 24 participants who have used only originators, their responses to the ...

Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

After seven years on the market, 150 million systems, and more than 1 billion games sold, Nintendo has finally announced the Nintendo Switch 2. The rumor mill was heating up in January ...

Symphony biosimilar approval is expected by year-end ... on current patients that it will not be a full heart switch. So there might be towards second half of the year more momentum on the ...

The best modern TVs come with a few HDMI 2.1 and 2.0 ports to help you connect all your devices together, but if that's not enough, or you want greater control without reaching behind the TV, an ...

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...